We carried out a study to determine the spectrum of bacterial isolates from surgical-site infections (SSIs) and their antimicrobial susceptibility pattern at Armed Forces Institute of Pathology, Rawalpindi in collaboration with Combined Military Hospital (CMH), Rawalpindi. Bacterial isolates were identified by standard techniques and their antimicrobial susceptibility was done by modified Kirby-Bauer disc diffusion technique. A total of -123 isolates were recovered from -78 patients, most of which were cases of orthopaedic (n=35) and abdominal (n=21) surgery. Staphylococcus aureus (n=39) was the most frequently isolated pathogen followed by Pseudomonas aerations (n=21), Escherichia coil (n=19) and Acinetobacter spp. (n=11). Methicillin resistant staphylococcus aureus (MR5A), resistant to multiple antimicrobials accounted for 77% of Staphylococcus aureus isolates. None of the MRSA isolates was found resistant to vancomycin. More than 58% of isolates of enterobacteriaceae and Acinetobacter spp. were resistant to ampicillin, doxycycline, gentamicin, amikacin, trimethoprim-sulphamethoxazole, cephradine, ceftriaxone, cefpirome, and ofloxacin. Resistance of enterobacteriaceae to other antimicrobials was: cefepime, 48%; amikacin, 58.3%, piperacillin-tazobactam, 16.7% and imipenem, 4.2% whereas that of Acinetobacter spp. was; amikacin, 45.45%; cefepime, 54.54%, piperacillin-tazobactam, 27.27% and imipenem, 18.18%. More than half of the Pseudomonas aeruginosa isolates were resistant to aminoglycoside while one third were resistant to ofloxacin and ceftazidime. Resistance to other antimicrobials was: cefpirome, 42.9%; cefepime, 9.5%; cefoperazone, 14.3% and piperacillin-tazobactam, 4.8%; while none of the Pseudomonas aeruginosa isolate was resistant to imipenem. MRSA and multi-drug resistant enterobacteriaceae were the major cause of the nosocomial SSIs at CMH, Rawalpindi. In such infections before initiation of antimicrobial treatment, appropriate specimens for culture and sensitivity should be collected. In critically ill patients, till susceptibility results are available, empirical therapy with a combination of vancomycin and piperacillin-tazobactam or imipenem is recommended.